Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
Alto crecimiento
Los ingresos de la empresa han crecido de manera constante durante los últimos tres años, con un promedio interanual del 69.11%.
Creciendo
La empresa se encuentra en una fase de crecimiento. Sus ingresos anuales más recientes ascienden a 1.20M USD.
Valorada de forma justa
El PE más reciente de la empresa es -0.61, en un rango percentil medio de 3 años.
Compra institucional
Las tenencias institucionales más recientes son 2.25M acciones, lo que supone un aumento del 33.51% con respecto al trimestre anterior.